

# CITATION REPORT

List of articles citing

## Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials

DOI: 10.1001/jamaophthalmol.2018.1544  
JAMA Ophthalmology, 2018, 136, 666-677.

**Source:** <https://exaly.com/paper-pdf/69243286/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
226	Age-related macular degeneration. <b>2018</b> , 392, 1147-1159		455
225	Lessons from Recent Phase III Trial Failures: Don't Design Phase III Trials Based on Retrospective Subgroup Analyses from Phase II Trials. <b>2018</b> , 125, 1488-1491		16
224	Stargardt macular dystrophy and evolving therapies. <b>2018</b> , 18, 1049-1059		29
223	Prioritising research into age-related macular degeneration. <b>2019</b> , 30, 10-17		
222	Clinical promise of next-generation complement therapeutics. <b>2019</b> , 18, 707-729		148
221	Complement system and age-related macular degeneration: drugs and challenges. <b>2019</b> , 13, 2413-2425		35
220	Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye. <b>2019</b> , 14, e0218613		15
219	Systemic expression of Alu RNA in patients with geographic atrophy secondary to age-related macular degeneration. <b>2019</b> , 14, e0220887		2
218	[Pharmacotherapy of Non-neovascular AMD]. <b>2019</b> , 236, 1076-1080		0
217	Complement inhibition as a therapeutic strategy in retinal disorders. <b>2019</b> , 19, 335-342		54
216	Microperimetry for geographic atrophy secondary to age-related macular degeneration. <b>2019</b> , 64, 353-364		14
215	The Challenges and Promise of Complement Therapeutics for Ocular Diseases. <b>2019</b> , 10, 1007		39
214	When Genetics Can Point Researchers and Clinicians in New Directions. <i>JAMA Ophthalmology</i> , <b>2019</b> , 137, 876-877	3.9	1
213	Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. <b>2019</b> , 19, 735-751		13
212	Fellow Eye Status Is a Biomarker for the Progression Rate of Geographic Atrophy: A Systematic Review and Meta-analysis. <b>2019</b> , 3, 305-315		12
211	Precursors and Development of Geographic Atrophy with Autofluorescence Imaging: Age-Related Eye Disease Study 2 Report Number 18. <b>2019</b> , 3, 724-733		10
210	Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. <b>2019</b> , 20,		27

209	VEGF in Signaling and Disease: Beyond Discovery and Development. <b>2019</b> , 176, 1248-1264	617
208	David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments. <b>2019</b> , 8,	63
207	Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development. <b>2019</b> , 36, 58	20
206	Apolipoprotein A-I Mimetic Peptide L-4F Removes Bruch's Membrane Lipids in Aged Nonhuman Primates. <b>2019</b> , 60, 461-472	19
205	Retinal neuroprotection: current strategies and future directions. <b>2019</b> , 30, 199-205	17
204	CLINICOPATHOLOGIC CORRELATION OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <b>2019</b> , 39, 802-816	28
203	The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. <b>2019</b> , 69, 116-136	38
202	In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. <b>2019</b> , 16, 86-95	1
201	Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. <b>2020</b> , 127, 523-532	13
200	Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4. <b>2020</b> , 127, 394-409	67
199	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. <b>2020</b> , 127, 186-195	101
198	Age-related macular degeneration: A two-level model hypothesis. <b>2020</b> , 76, 100825	58
197	Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. <b>2020</b> , 105, 145-163	13
196	Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. <b>2020</b> , 127, 769-783	22
195	Age-Related Macular Degeneration Preferred Practice Pattern . <b>2020</b> , 127, P1-P65	76
194	Mitochondrial Defects Drive Degenerative Retinal Diseases. <b>2020</b> , 26, 105-118	35
193	The role of lymphocytes and phagocytes in age-related macular degeneration (AMD). <b>2020</b> , 77, 781-788	15
192	Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion. <b>2020</b> , 127, 648-659	20

191	Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. <b>2020</b> , 210, 86-96		7
190	Complement-Mediated Microglial Phagocytosis and Pathological Changes in the Development and Degeneration of the Visual System. <b>2020</b> , 11, 566892		7
189	Progression of Unifocal versus Multifocal Geographic Atrophy in Age-Related Macular Degeneration: A Systematic Review and Meta-analysis. <b>2020</b> , 4, 899-910		11
188	[On the inflammatory origins of AMD]. <b>2020</b> , 36, 886-892		3
187	The evolution of data ethics in clinical research and drug development. <b>2020</b> , 14, 100517		0
186	Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials. <b>2020</b> , 4, 673-688		14
185	Multimodal Evaluation of Visual Function in Geographic Atrophy versus Normal Eyes. <b>2020</b> , 14, 1533-1545		3
184	Plasma biomarkers of the amyloid pathway are associated with geographic atrophy secondary to age-related macular degeneration. <b>2020</b> , 15, e0236283		5
183	Growth Rate of Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Meta-Analysis of Natural History Studies and Implications for Designing Future Trials. <b>2021</b> , 64, 205-215		4
182	Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease. <b>2020</b> , 125-160		2
181	Unbiased identification of novel subclinical imaging biomarkers using unsupervised deep learning. <b>2020</b> , 10, 12954		8
180	Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration. <i>JAMA Ophthalmology</i> , <b>2020</b> , 138, 1026-1034	3.9	21
179	Slowed Progression of Age-Related Geographic Atrophy Following Subthreshold Laser. <b>2020</b> , 14, 2983-2993		4
178	Multimodal Imaging for the Assessment of Geographic Atrophy in Patients with "Foveal" and "No-Foveal" Sparing. <b>2021</b> , 64, 675-683		0
177	Potential Therapeutic Benefit of NAD Supplementation for Glaucoma and Age-Related Macular Degeneration. <b>2020</b> , 12,		10
176	Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases. <b>2020</b> ,		0
175	Geographic Atrophy Growth Is Strongly Related to Lesion Perimeter: Unifying Effects of Lesion Area, Number, and Circularity on Growth. <b>2021</b> , 5, 868-878		9
174	Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. <b>2021</b> , 83, 100936		6

173	An exploratory study to evaluate visual function endpoints in non-advanced age-related macular degeneration. <b>2020</b> , 20, 424	1
172	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. <b>2020</b> , 21,	20
171	Genotype- and Phenotype-Based Subgroups in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The EYE-RISK Consortium. <b>2020</b> , 4, 1129-1137	12
170	Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration. <b>2020</b> , 61, 63	10
169	Test-retest variability of microperimetry in geographic atrophy. <b>2020</b> , 6, 16	3
168	State-of-the art pharmacotherapy for non-neovascular age-related macular degeneration. <b>2020</b> , 21, 773-784	7
167	Modulation of inflammatory processes by thermal stimulating and RPE regenerative laser therapies in age related macular degeneration mouse models. <b>2020</b> , 2, 100031	2
166	Hyperreflective Foci and Specks Are Associated with Delayed Rod-Mediated Dark Adaptation in Nonneovascular Age-Related Macular Degeneration. <b>2020</b> , 4, 1059-1068	13
165	A Novel Eye Drop Candidate for Age-Related Macular Degeneration Treatment: Studies on its Pharmacokinetics and Distribution in Rats and Rabbits. <b>2020</b> , 25,	1
164	New therapeutic targets in the treatment of age-related macular degeneration. <b>2020</b> , 95, 75-83	2
163	Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina. <b>2020</b> , 15, e0226311	1
162	C3 Function and Inhibition in Geographic Atrophy: Interesting Insights from a Phase 2 Study. <b>2020</b> , 127, 196-197	5
161	Retinal degeneration. <b>2020</b> , 1145-1162	
160	Regression to the Mean in Measurements of Growth Rates in Geographic Atrophy. <b>2020</b> , 63, 460-465	1
159	Determinants of Cone and Rod Functions in Geographic Atrophy: AI-Based Structure-Function Correlation. <b>2020</b> , 217, 162-173	18
158	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. <b>2020</b> , 214, 108391	7
157	Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials. <b>2021</b> , 82, 100907	17
156	Age-related macular degeneration masqueraders: From the obvious to the obscure. <b>2021</b> , 66, 153-182	1

155	Revisiting the role of factor H in age-related macular degeneration: Insights from complement-mediated renal disease and rare genetic variants. <b>2021</b> , 66, 378-401	7
154	The pathogenesis of age-related macular degeneration is not inflammatory mediated but is instead due to immunosenescence-related failure of tissue repair. <b>2021</b> , 146, 110392	2
153	Progress in developing rodent models of age-related macular degeneration (AMD). <b>2021</b> , 203, 108404	6
152	Clinical Course of Treated Choroidal Neovascularization in Eyes with Pre-existing Geographic Atrophy: Case Series and Reappraisal of the Literature. <b>2021</b> , 46, 988-994	1
151	C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. <b>2021</b> , 128, 576-586	70
150	Understanding metabolism related differences in ocular efficacy of MGV354. <b>2021</b> , 51, 5-14	
149	Histopathology of Age-Related Macular Degeneration and Implications for Pathogenesis and Therapy. <b>2021</b> , 1256, 67-88	
148	Pharmacotherapy of Age-Related Macular Degeneration. <b>2021</b> , 1-26	
147	Age-Related Macular Degeneration Revisited: From Pathology and Cellular Stress to Potential Therapies. <b>2020</b> , 8, 612812	13
146	Gene Therapy in the Treatment of Geographic Atrophy. <b>2021</b> , 61, 241-247	
145	The Need for Alternative Therapies in Eye Disorders. <b>2021</b> , 425-434	
144	Emerging treatments for geographic atrophy in age-related macular degeneration. <b>2021</b> , 32, 294-300	1
143	Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. <b>2021</b> ,	21
142	Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning Applications. <b>2021</b> , 10, 4	6
141	An Overview of Age-Related Macular Degeneration: Clinical, Pre-Clinical Animal Models and Bidirectional Translation.	2
140	AI-based structure-function correlation in age-related macular degeneration. <b>2021</b> , 35, 2110-2118	2
139	Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration. <b>2021</b> , 35, 303-323	0
138	New Drugs in the Pipeline for the Management of AMD.	

137	Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study. <b>2021</b> , 11, e049495	1
136	Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice. <b>2021</b> , 12, 681098	1
135	Emerging therapies and their delivery for treating age-related macular degeneration. <b>2021</b> ,	6
134	Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576-586). <b>2021</b> , 128, e25-e26	2
133	Age-related macular degeneration. <b>2021</b> , 7, 31	71
132	Antisense Oligonucleotide Therapy for Ophthalmic Conditions. <b>2021</b> , 36, 452-457	1
131	Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration. <b>2021</b> , 232, 49-57	1
130	The Use of Neuroprotective Agents in Treating Geographic Atrophy. <b>2021</b> , 64, 888-902	0
129	Age-Related Macular Degeneration: Pathophysiology, Management, and Future Perspectives. <b>2021</b> ,	8
128	Halting targeted and collateral damage to red blood cells by the complement system. <b>2021</b> , 43, 799-816	2
127	A Review of Completed and Ongoing Complement Inhibitor Trials for Geographic Atrophy Secondary to Age-Related Macular Degeneration. <b>2021</b> , 10,	8
126	Macular Degeneration, Age Related. 2, 1-10	
125	Interlink between Inflammation and Oxidative Stress in Age-Related Macular Degeneration: Role of Complement Factor H. <b>2021</b> , 9,	5
124	Conversion from Intermediate Age-Related Macular Degeneration to Geographic Atrophy in a Proxima B Subcohort Using a Multimodal Approach. <b>2021</b> ,	0
123	Pathogenic mechanisms contributing to the vulnerability of aging human photoreceptor cells. <b>2021</b> , 35, 2917-2929	6
122	Interactions between Apolipoprotein E Metabolism and Retinal Inflammation in Age-Related Macular Degeneration. <b>2021</b> , 11,	2
121	Differential and Altered Spatial Distribution of Complement Expression in Age-Related Macular Degeneration. <b>2021</b> , 62, 26	4
120	Long-term progression of geographic atrophy in age-related macular degeneration does the phakic status matter?. <b>2021</b> , 259, 3711-3719	0

119	Complement Inhibition for Geographic Atrophy: A Tempting Target with Mixed Results. <b>2021</b> , 10,	0
118	Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. <b>2021</b> , 2021, 9945725	2
117	Therapeutic Margin for Geographic Atrophy: The Race Between Longevity and Disease Progression. <i>JAMA Ophthalmology</i> , <b>2021</b> , 139, 751-752	3.9 0
116	Transcriptomic and proteomic retinal pigment epithelium signatures of age-related macular degeneration.	1
115	Progression of geographic atrophy. <b>2021</b> , 16, 343-356	
114	COMPARISON OF SPECTRALIS AND CIRRUS OPTICAL COHERENCE TOMOGRAPHY FOR THE DETECTION OF INCOMPLETE AND COMPLETE RETINAL PIGMENT EPITHELIUM AND OUTER RETINAL ATROPHY. <b>2021</b> , 41, 1851-1857	1
113	Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. <b>2021</b> , 235, 131-142	0
112	Implications of genetic variation in the complement system in age-related macular degeneration. <b>2021</b> , 84, 100952	10
111	Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. <b>2021</b> , 128, 1325-1336	11
110	Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. <b>2021</b> , 12, 712572	3
109	Incidence of Newly Registered Blindness From Age-Related Macular Degeneration in Australia Over a 21-Year Period: 1996-2016. <b>2021</b> , 10, 442-449	2
108	Transplantation of Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in a Swine Model of Geographic Atrophy. <b>2021</b> , 22,	2
107	Unravelling the therapeutic potential of IL-33 for atrophic AMD. <b>2021</b> ,	1
106	Natural history of incomplete retinal pigment epithelial and outer retinal atrophy in age-related macular degeneration. <b>2021</b> , 56, 325-334	2
105	Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study. <b>2021</b> , 3, e665-e675	3
104	Therapy in pipeline for age-related macular degeneration. <b>2022</b> , 233-260	
103	Current Management of Age-Related Macular Degeneration. <b>2021</b> , 1256, 295-314	1
102	Effect of Human Central Nervous System Stem Cell Subretinal Transplantation on Progression of Geographic Atrophy Secondary to Nonneovascular Age-Related Macular Degeneration. <b>2021</b> , 5, 32-40	3



101	Functional Assessment of Vision Restoration. <b>2019</b> , 1185, 145-149	4
100	Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy. <b>2021</b> , 38, 17-27	3
99	New therapeutic targets in the treatment of age-related macular degeneration. <b>2020</b> , 95, 75-83	7
98	Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial. <b>2020</b> , 4, 889-898	8
97	Photoreceptor metabolic reprogramming: current understanding and therapeutic implications. <b>2021</b> , 4, 245	8
96	PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <b>2021</b> , 41, 144-155	18
95	Topographic Variation of the Growth Rate of Geographic Atrophy in Nonexudative Age-Related Macular Degeneration: A Systematic Review and Meta-analysis. <b>2020</b> , 61, 2	15
94	Effects of senescent secretory phenotype acquisition on human retinal pigment epithelial stem cells. <b>2018</b> , 10, 3173-3184	8
93	Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration. <b>2020</b> , 14, 83-94	9
92	Pharmacological Advances in the Treatment of Age-related Macular Degeneration. <b>2020</b> , 27, 583-598	11
91	Age-related Macular Degeneration: Current Knowledge of Zinc Metalloproteinases Involvement. <b>2019</b> , 20, 903-918	3
90	The Diagnosis and Treatment of Age-Related Macular Degeneration. <b>2020</b> , 117, 513-520	21
89	Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. <b>2020</b> , 11, 578069	4
88	Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brovacumab, Abicipar, and the Port Delivery System. <b>2018</b> , 49, 913-917	10
87	Targeting senescent retinal pigment epithelial cells facilitates retinal regeneration in mouse models of age-related macular degeneration. <b>2021</b> , 43, 2809-2833	5
86	At What Age Does Age-Related Macular Degeneration Start?. <i>JAMA Ophthalmology</i> , <b>2021</b> , 139, 1226-1237	9
85	Therapeutic potential of PGC-1 $\alpha$ in age-related macular degeneration (AMD) - the involvement of mitochondrial quality control, autophagy, and antioxidant response. <b>2021</b> , 25, 773-785	2
84	Tipping the balance: intricate roles of the complement system in disease and therapy. <b>2021</b> , 43, 757-771	6

- 83 Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina.
- 82 Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD. **2020**, 1-53
- 81 Local Progression Kinetics of Geographic Atrophy Depends Upon the Border Location. **2021**, 62, 28 0
- 80 Genotype-Phenotype Analysis of Atrophic Age-Related Macular Degeneration: What Does It Mean When You Don't Find What You Were Expecting?. **2021**, 5, 1059-1060
- 79 Acadesine suppresses TNF- $\alpha$ -induced complement component 3 (C3), in retinal pigment epithelial (RPE) cells. **2020**, 15, e0244307 1
- 78 Clinical Trials Related to Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. **2020**, 259-281 0
- 77 Dry Age-Related Macular Degeneration. **2020**, 1-12
- 76 Applications of Artificial Intelligence for the Diagnosis, Prognosis, and Treatment of Age-related Macular Degeneration. **2020**, 60, 147-168 0
- 75 Reliability of retinal pathology quantification in age-related macular degeneration: Implications for clinical trials and machine learning applications.
- 74 Quantitative cone contrast threshold testing in patients with differing pathophysiological mechanisms causing retinal diseases.
- 73 The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization. **2020**, 26, 370-377 2
- 72 Progress of clinical therapies for dry age-related macular degeneration.. **2022**, 15, 157-166 2
- 71 Complement cascade inhibition in geographic atrophy: a review.. **2022**, 1
- 70 The NLRP3 inflammasome in age-related eye disease: Evidence-based connexin hemichannel therapeutics.. **2021**, 215, 108911 0
- 69 Complement Mediators in Development to Treat Age-Related Macular Degeneration.. **2022**, 39, 107 1
- 68 From data to deployment: the Collaborative Communities on Ophthalmic Imaging roadmap for artificial intelligence in age-related macular degeneration.. **2022**, 0
- 67 Newer therapeutic agents for retinal diseases. 1-15
- 66 Systemic Complement Activation Profiles in Nonexudative Age-Related Macular Degeneration: A Systematic Review. **2022**, 100118 2

65	Compstatins: the dawn of clinical C3-targeted complement inhibition.. <b>2022,</b>		2
64	Recent developments of neuroprotective agents for degenerative retinal disorders.. <b>2022, 17, 1919-1928</b>		2
63	Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.. <i>JAMA Ophthalmology</i> , <b>2022,</b>	3.9	0
62	Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options.. <b>2022, 23,</b>		2
61	A hierarchical Bayesian entry time realignment method to study the long-term natural history of diseases.. <b>2022, 12, 4869</b>		
60	Evaluating a causal relationship between Complement Factor I protein level and advanced age-related macular degeneration using Mendelian Randomisation. <b>2022, 100146</b>		0
59	Evolving Patterns of Hyperfluorescent Fundus Autofluorescence Accompany Retinal Atrophy in the Rat and Mimic Atrophic Age-Related Macular Degeneration.. <b>2022, 11, 3</b>		
58	Correlation between Fundus Autofluorescence and En Face Optical Coherence Tomography Measurements of Geographic Atrophy.. <b>2022,</b>		0
57	Epithelial phenotype restoring drugs suppress macular degeneration phenotypes in an iPSC model.. <b>2021, 12, 7293</b>		3
56	Retinal findings in glomerulonephritis. <b>2021, 1-13</b>		0
55	Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies.. <b>2022, 13, 855743</b>		0
54	Intravitreal application of epidermal growth factor in non-exudative age-related macular degeneration. <b>2021,</b>		
53	Pharmacotherapy of Age-Related Macular Degeneration. <b>2022, 3619-3644</b>		
52	Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD. <b>2022, 3565-3617</b>		
51	Adherence to the Mediterranean-Style Eating Pattern and Macular Degeneration: A Systematic Review of Observational Studies. <b>2022, 14, 2028</b>		1
50	Minimizing Risks to Patients by Improving Presentation of Clinical Trial Results in Geographic Atrophy Trials.. <b>2022, 6, 337-338</b>		0
49	Perspectives from clinical trials: is geographic atrophy one disease?.		0
48	Impact of Cataract Surgery on Low Luminance Visual Acuity Deficit Measurements. <b>2022, 100170</b>		0

47	Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. <b>2022</b> , 14,	1
46	The effect of pegcetacoplan treatment on photoreceptor maintenance in geographic atrophy monitored by AI-based OCT analysis. <b>2022</b> ,	0
45	Bench-to-Bedside Research in Ophthalmology. <b>2022</b> , 67-124	
44	Association of Complement C3 Inhibitor Pegcetacoplan with Photoreceptor Degeneration Beyond Areas of Geographic Atrophy.	
43	As in Real Estate, Location Matters: Cellular Expression of Complement Varies Between Macular and Peripheral Regions of the Retina and Supporting Tissues. 13,	0
42	Emerging opportunities for C3 inhibition in the eye. <b>2022</b> , 101633	0
41	Protective effects of CRTH2 suppression in dry age-related macular degeneration. <b>2022</b> ,	1
40	Molecular Genetic Mechanisms in Age-Related Macular Degeneration. <b>2022</b> , 13, 1233	
39	Transcriptomic and proteomic retinal pigment epithelium signatures of age-related macular degeneration. <b>2022</b> , 13,	1
38	Complement 3a Mediates CCN2/CTGF in Human Retinal Pigment Epithelial Cells. <b>2022</b> , 2022, 1-8	
37	The role of the complement system in Multiple Sclerosis: A review. 13,	0
36	A Clinical and Preclinical Assessment of Clinical Trials for Dry Age-related Macular Degeneration. <b>2022</b> , 100213	
35	Automated Identification of Incomplete and Complete Retinal Epithelial Pigment and Outer Retinal Atrophy Using Machine Learning. <b>2022</b> ,	0
34	Investigational drugs in clinical trials for macular degeneration.	1
33	Targeting the Complement Cascade for Treatment of Dry Age-Related Macular Degeneration. <b>2022</b> , 10, 1884	0
32	Sodium butyrate-loaded nanoparticles coated with chitosan for the treatment of neovascularization in age-related macular degeneration: Ocular biocompatibility and antiangiogenic activity. <b>2022</b> , 179, 26-36	0
31	Does the Outer Retinal Thickness Around Geographic Atrophy Represent Another Clinical Biomarker for Predicting Growth?. <b>2022</b> , 244, 79-87	1
30	Uncertainty-Aware Geographic Atrophy Progression Prediction from Fundus Autofluorescence. <b>2022</b> , 29-38	0

29	Deep Learning to Predict Geographic Atrophy Area and Growth Rate from Multimodal Imaging. <b>2022,</b>	0
28	Risk Factors for Progression of Age-Related Macular Degeneration: Population-Based Amish Eye Study. <b>2022, 11, 5110</b>	1
27	The influence of the topographic location of geographic atrophy on vision-related quality of life in nonexudative age-related macular degeneration.	0
26	Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential. <b>2022, 23, 13280</b>	0
25	Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies. <b>2022, 11, 37</b>	1
24	Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. <b>2022, 12,</b>	0
23	C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degeneration. <b>2022, 8,</b>	0
22	Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.	0
21	Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review. <b>2022, 23, 14759</b>	0
20	Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision. <b>2022, 20,</b>	1
19	Les inhibiteurs du complément : une vue d'ensemble. <b>2022, 43, 703-712</b>	0
18	Endpoints for clinical trials in ophthalmology. <b>2023, 101160</b>	0
17	LIGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration.	0
16	Controversies and Disparities in the Management of Age-Related Macular Degeneration. 1-9	0
15	Role of flavonoids in age-related macular degeneration. <b>2023, 159, 114259</b>	1
14	Geographic atrophy phenotypes in subjects of different ethnicity: Asia-Pacific Ocular Imaging Society Workgroup Report 3. <b>2022,</b>	0
13	The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation. <b>2023, 12,</b>	0
12	Implementing Predictive Models in Artificial Intelligence through OCT Biomarkers for Age-Related &#x0D; Macular Degeneration. <b>2023, 10, 149</b>	0

- 11 Quantitative cone contrast threshold testing in patients with differing pathophysiological mechanisms causing retinal diseases. **2023**, 9,
- 10 Towards a Therapy for Geographic Atrophy: A Patient's Experience. Volume 17, 299-310
- 9 Complement Inhibitors for the Treatment of Geographic Atrophy. **2023**, 54, 66-70
- 8 Alternative Complement Pathway Inhibition by Lampalizumab: Analysis of Data from Chroma and Spectri Phase 3 Clinical Trials. **2023**, 100286
- 7 Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. **2023**, 21,
- 6 Randomized Phase 2b Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-related Macular Degeneration. **2023**,
- 5 Microperimetry in Retinal Diseases. **2023**, 12, 211-227
- 4 The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy: Analysis of the Phase 3 Chroma and Spectri Trials. **2023**, 100301
- 3 Ocular Delivery of Therapeutic Agents by Cell-Penetrating Peptides. **2023**, 12, 1071
- 2 Advanced Therapy Medicinal Products for Age-Related Macular Degeneration; Scaffold Fabrication and Delivery Methods. **2023**, 16, 620
- 1 Homeostasis and dyshomeostasis of the retina. **2023**, 2,